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Aims: The oxidized low-density lipoprotein receptor LOX-1 is up-regulated on activated endothelial cells, for example, the endothelium
of atherosclerosis-prone sites, in both human and animal models. We examined whether endothelial LOX-1 overexpression may contribute
to atherogenesis. Methods: Adenoviral vectors expressing LOX-1 or LOXIN (a splice variant of LOX-1 with inhibitory function) were
created and used to transduce the normally lesion-free common carotid artery, in high fat-fed female ApoE−/− mice. Mice were placed on
high-fat diet for 4 weeks prior to gene transfer with either LOX-1 or a combination of LOX-1 and LOXIN, and assessment of plaque
development analyzed 6 weeks following gene transfer. Results: Compared to controls, LOX-1 transduction induced a significant increase
in plaque coverage within the common carotid artery to 91% compared to 50% after RAd66 control virus infection (P≤.05). This was
inhibited by co-expression of LOXIN (62%). Conclusions: These results demonstrate that up-regulation of LOX-1 promotes atherogenesis,
highlighting LOX-1 function as a target for intervention. In addition, this study further demonstrated the inhibitory function of LOXIN.
n 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Keywords: LOX-1; OLR1; Atherogenesis; LOXIN; Splice variant1. Introduction
LOX-1 is a lectin-like oxidized LDL receptor (also known
as oxidized LDL receptor 1—OLR1), which was initially
described in endothelial cells by Sawamura et al. [1]. LOX-1
expression has subsequently been described in both smooth
muscle cells and macrophage in atherosclerotic plaques [2]
as well as in other cell types including adipocytes [3],
platelets [4], and chondrocytes [5]. LOX-1 expression can beAbbreviation: ROS, reactive oxygen species; LOX-1, lectin-like
oxidized LDL receptor.
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which are involved in the atherosclerotic process, including
hypertension, sepsis, inflammatory mediators, dyslipidemia,
advanced glycation end products, and fluid shear stress
(reviewed in Ref. [6]). LOX-1 performs a number of
functions in addition to oxidized LDL (oxLDL) binding,
such as binding of apoptotic cell bodies and aged red blood
cells [7] and acting as a leukocyte adhesion molecule [8].
Binding of oxLDL to LOX-1 induces endothelial dysfunc-
tion and apoptosis, stimulating reactive oxygen species
(ROS) production and NFκB activation [9], strongly linking
LOX-1 with the process of atherosclerosis [6,10].
Several studies in hyperlipidemic mice have demonstrated
a link between LOX-1 and atherosclerosis. Mehta et al. [11]
created a LOX-1−/−/LDLR−/− mouse, which on high-fat diet
exhibited reduced plaque development in the aorta compared
to controls. In addition, the LOX-1−/−/LDLR−/− mice also
demonstrated a number of anti-atherosclerotic features, e.g.,
increased IL-10 levels and eNOS activity, with a concomitant
reduction in MAPK p38 and NFκB activation. Inoue et al.
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LOX-1 was overexpressed in multiple cell types including
vascular and cardiac tissue. Among the pathologies
displayed in this transgenic mouse was an increase in ox-
LDL uptake and atheroma-like lesions in coronary arteries.
In addition, Ishigaki et al. [13] used an adenoviral vector to
overexpress LOX-1 in the liver, enhancing hepatic uptake
of ox-LDL and reducing atheroma in the aorta. Taken
together, these experiments clearly demonstrated a role for
LOX-1 in atherosclerosis, although the contribution of endo-
thelial vs. smooth muscle cell or macrophage expression has
yet to be determined.
LOXIN is a splice variant of LOX-1, the expression of
which is increased by single nucleotide polymorphisms
(SNPs) which have been associated with a lower incidence
of myocardial infarction [14]. LOXIN forms heterodimers
with LOX-1, preventing cell surface localization and
function [14,15].
To examine the consequence of selective endothelial
expression of LOX-1 in atherosclerosis, we used adenoviral
gene transfer of LOX-1 in the common carotid artery. We
found that overexpression of LOX-1 enhances atherogenesis
and that LOXIN inhibits the development of plaque induced
by LOX-1 overexpression.2. Materials and methods
2.1. Construction of viruses
Plasmids containing the cDNA for both LOX-1 and
LOXIN were a generous gift from Prof. Giuseppe Novelli.
The expression cassette from pCpG-mcs (InvivoGen, San
Diego, CA, USA) containing the mCMV enhancer, EF1α
promoter, small synthetic intron, and polyA signal was
removed by EcoRI digest and cloned into pDC511 (Microbix
Biosystems, Canada). The cDNAs for LOX-1 and LOXIN
were amplified by PCR using KOD proofreading polymerase
with primers SW187F 5′ GCGCAGGCCTCCCGCCAT-
GACTTTTGATGACC, which created a StuI restriction site
and optimized the KOZAK sequence, and SW188R
5′ CGGCGCTAGCTAAAATGCAGTTTTC, which created
a NheI restriction site. The NcoI site within the multiple
cloning site of the expression cassette was removed by
digestion, blunting, and relegation, and the amplified cDNAs
for LOX-1 and LOXIN cloned in StuI/NheI. Adenoviral
vectors were produced using the Microbix Biosystems kit
according to their protocols. RAd66 [16], an Ad-null empty
virus, was used to control for virus-induced inflammation.
2.2. In vivo delivery of adenoviral vectors
All experiments were performed according to home office
guidelines and approved by the local ethics committee for
animal experimentation. Eight-week-old female ApoE−/−
mice were placed on high-fat diet (containing 21% lard and0.15% cholesterol) 4 weeks prior to gene delivery, to induce
hypercholesterolemia and then maintained on high-fat diet
for the remainder of the experiment (n=6 per group).
Adenoviral transduction of carotid arteries was performed
by luminal incubation of each vector for 10 min without
silastic collar placement as described [17] (see Supplemen-
tary Information). Viruses were diluted to 1×1010 pfu/ml
using the dialysis buffer used to prepare the adenoviral
vector stocks [10 mM Tris (pH 7.5), 135 mM NaCl, 1 mM
MgCl2, 10% v/v glycerol], to ensure that all transductions
were performed under the same conditions, the vehicle
control just contained dialysis buffer. For investigating the
effects of LOXIN on LOX-1-induced atherogenesis, 1×1010
pfu/ml of each vector was used (total 2×1010 pfu/ml); hence
2×1010 pfu/ml of the control virus RAd66 was used as a
control for this group (labelled RAd66 high). Six weeks
following transduction, mice were sacrificed and perfusion
fixed with 4% formaldehyde for 5 min. The carotids were
exposed, cut longitudinally, and excised before being pinned
out flat and fixed for a further 24 h. The fixed arteries were
then immobilized in agar, processed, and paraffin embedded
so that longitudinal sections of the carotids could be cut.
2.3. Measurement of plaque area
Longitudinal sections (3 μm) were cut through the whole
width of the carotid artery. Measurement of the percentage of
section covered by plaque was performed every 25 sections
(75 μm) through the width of the artery. An average of 6.75
measurements was made per carotid. To standardize the
analysis, measurement of plaque coverage was performed on
the field of view 500 μm below the carotid bifurcation. This
avoids the potential for plaque initiation due to either the
turbulent shear stress experienced around the bifurcation or
the mechanical damage to the endothelium during gene
transfer. The average length analyzed for plaque coverage
was ∼1400 μm the length of internal elastic lamina. The data
was normally distributed within each group, and differences
between groups were analyzed using one-way analysis of
variance (ANOVA), using Tukey–Kramer multiple compar-
isons post hoc test.
2.4. Immunohistochemical analysis of LOX-1 expression
In a separate cohort of mice, gene transfer of either LOX-1
or RAd66 was performed and the mice sacrificed after 7 days.
Both the transduced and nontransduced arteries were taken
and snap frozen in OCT compound (BDH), orientated to
allow transverse sections to be cut. Seven-micrometer-thick
frozen sections were cut, air dried, and fixed in methanol with
0.3% H2O2 for 10 min. Human LOX-1 expression was
visualized using goat anti-human LOX-1 antibody (5 μg/ml,
AF1798, R&D Systems, Abingdon, UK) or matched
nonimmune goat control, with 1/400 biotinylated rabbit
anti-goat secondary antibody (DAKO, Ely, UK) and 1/200
extravidin HRP conjugate (Sigma, Poole, UK) with SIGMA
Fig. 1. (A–C) Immunohistochemical analysis of LOX-1 expression, 1 week following gene transfer. (A) Anti-LOX-1 antibody; (B) nonimmune goat control; (C)
anti-LOX-1 antibody on RAd66 control transduced artery. Intense staining of luminal cells was observed, which by position and shape were predominantly
identified as endothelial cells. (D–F) Representative longitudinal sections of transduced arteries 6 weeks post gene transfer. (D) Vehicle control treated; (E)
RAd66 control virus transduced; (F) AdLOX-1-transduced artery.
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were counterstained with hematoxylin for 30 s.Fig. 2. Measurement of plaque coverage in vehicle, RAd66 control (1×1010
pfu/ml), LOX-1 (1×1010 pfu/ml), LOXIN LOX-1 (1×1010 pfu/ml), RAd66
high control (2×1010 pfu/ml), and LOX-1/LOXIN (1×1010 pfu/ml of each
vector) transduced arteries. Analysis of plaque coverage in the test region
identified a significant increase in plaque coverage in the AdLOX-1-
transduced carotid artery compared to RAd66 control and vehicle-
transduced artery using one-way ANOVA (PN.05 and N.001, respectively).3. Results
3.1. LOX-1 overexpression contributes to atherogenesis
In order to test the potential of endothelial LOX-1
overexpression to contribute to atherogenesis, we performed
luminal gene transfer using an adenoviral vector. Ten-minute
luminal incubation of the vector, or an empty virus control
(RAd66), was sufficient to achieve gene transfer, detected by
immunohistochemistry on transduced vessels (Fig. 1A–C).
Only cells on the surface of the lumen stained for human
LOX-1, showing that the technique selectively transduces
endothelial cells, in agreement with previous reports [18].
To assess the impact of endothelial LOX-1 overexpres-
sion on the development of atherosclerosis, carotid arteries
were examined 6 weeks following gene transfer, in
hyperlipidemic ApoE−/− mice, without the placement of
any flow-modifying cuffs or collars. Transduced arteries
were removed, opened up, and sectioned longitudinally to
allow the area of the vessel surface covered by plaque to be
assessed along the vessel (Fig. 1D–F). There was
significantly more plaque coverage in arteries transduced
by LOX-1 compared to controls, with an average of 91%
coverage vs. 50% RAd66 control virus (Fig. 2, P≤.05).Infection with RAd66 alone increased plaque coverage
(50% compared to 30%) compared to vehicle, although this
failed to reach significance.
3.2. LOXIN ameliorates LOX-1 contribution to atherogenesis
In order to assess the effect of co-expressing the
‘dominant-negative’ splice variant LOXIN on the LOX-1
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both vectors as part of the same experiment. We chose to
keep the concentration of LOX-1 vector the same (1×1010
pfu/ml) and supplement it with an equal concentration of
LOXIN vector. As the total concentration of virus was
double, a separate control group was used with 2×1010
pfu/ml RAd66 (Fig. 2). Carotid arteries transduced by
LOX-1 and LOXIN together show no difference in plaque
coverage compared to the high-dose RAd66 control (62% vs.
60%). Hence co-expression of LOXINwith LOX-1 abolishes
its atherogenic effect. Again, a trend towards greater plaque
coverage was observed in the high-dose RAd66 group
compared to vehicle alone (30% vs. 60%; P=.09), presum-
ably due to adenovirus-induced inflammation of the vessel
wall. The higher dose of RAd66 produced a small nonsig-
nificant increase in atherogenic effect compared to the lower
dose (60% vs. 50%).4. Discussion
We demonstrated here for the first time the ability of
endothelial LOX-1 overexpression to promote atherogenesis
in the common carotid artery of hyperlipidemic ApoE−/−
mice. This amplifies the conclusions from LOX-1-null mice
where the function of LOX-1 is deleted in other cell types,
including macrophage and smooth muscle cells. LOX-1 is
up-regulated in nondiseased but atheroprone arterial sites in
hyperlipidemic rabbits, in addition to early atherosclerotic
lesions in rabbits and humans [2,19]. The experiments
performed here suggest that endothelial LOX-1 expression
may have pathological consequences and is not simply a
passive marker of disturbed flow in atheroprone vascular
sites. We have also demonstrated experimentally for the first
time in an in vivo model that LOXIN is capable of inhibiting
the development of atherosclerosis that is induced by LOX-1
overexpression. This is in keeping with the human data,
which shows that SNPs that increase LOXIN expression are
linked to a lower event rate of acute coronary syndromes
[14]. The interpretation of the LOXIN-alone group is
difficult, as the overexpression of LOXIN in the absence
of LOX-1 is an unphysiological situation. LOXIN naturally
occurs at a roughly equivalent level compared to LOX-1 in
humans [14] and is able to inhibit LOX-1 cell surface
expression [14,15]; however, the effect of overexpressing
LOXIN in the absence of LOX-1 overexpression is unknown
and unphysiological. Mouse LOX-1 contains an exon not
present in humans; thus it is unclear whether human LOXIN
is able to interact with murine LOX-1. The presence of an
equivalent murine LOXIN splice variant in the mouse has
not been described.
The expression and action of LOX-1 have been widely
investigated and are the subject of many publications
(reviewed in Refs. [6,10]). One of the key mediators of
LOX-1 signalling is the activation and nuclear localization of
the transcription factor NFκB [9]. To assess NFκB activationin LOX-1-transduced arteries, we performed immunohisto-
chemistry for VCAM-1 and LOX-1 in sequential sections,
because VCAM-1 expression is NFκB dependent [20] and
has a role in the development of atherosclerosis [21].
However, we were unable to demonstrate a specific
differential up-regulation of VCAM-1 in LOX-1-transduced
cells because VCAM-1 expression was detected in all
endothelial cells, suggesting NFκB activation was ubiquitous
in this model (this may also be due to the semiquantitative
nature of immunohistochemistry limiting a difference in
expression from being observed—data not shown). The
precise mechanism(s) by which endothelial overexpression
of LOX-1 enhances atherosclerosis in this model is undefined
and is likely to be a combination of increased production of
ROS, NFκB activation, adhesion molecule expression, and
leukocyte binding and extravasation [6,10]. Thus a detailed
study of the pro-atherogenic mechanisms of LOX-1 in
endothelial cells in vivo is warranted.
We chose to perform these experiments in the common
carotid artery of hyperlipidemic mice because this site
normally remains free of atherosclerotic plaques even after
months of high-fat feeding, due to its lack of curvature and
side branches. Thus it is a good test site for the analysis of
genes which may have pro-atherogenic function. Adenoviral
vectors provide an efficient means of ectopically inducing
gene expression in the carotid artery; however, strong
expression from these vectors is not expected to last for more
than 2–3 weeks. This makes them useful for studies looking
at atherogenic gene function in the mouse hyperlipidemic
model, where atherosclerosis develops rapidly, enabling
even short-term transgene expression of proatherogenic
genes to initiate a lesion. Fibrotic deposition around
transduced arteries is observed in this model, as a response
to surgically induced injury. En face oil red O staining was
used to visualize lipid deposition in transduced and control
arteries (see Supplementary Information); however, there
was variable staining of the fibrotic tissue surrounding the
artery, with some arteries exhibiting significant perivascular
staining, presumably because of foam cell accumulation in
the surrounding tissue. Because it was not possible to
accurately discriminate between luminal and adventitial oil
red O staining in all the transduced arteries, measurement of
plaque area on longitudinal sections was used.
The approach used here worked well to examine the
proatherogenic effect of a cell-surface molecule, without the
need for creating a transgenic animal, allowing rapid analysis
of gene function. The experimental design should also work
for anti-atherogenic molecules, as the combination of
surgery and control virus induced significant initiation of
plaque coverage (no plaque is observed in unoperated
vessels—S. White, unpublished data). This gives the
possibility of a simple single procedure for observing either
pro- or anti-atherogenic effects of gene overexpression, in
the ApoE−/− mouse.
In conclusion, we have demonstrated that overexpression
of LOX-1 in the hyperlipidemic mouse was capable of
373S.J. White et al. / Cardiovascular Pathology 20 (2011) 369–373initiating atherosclerotic plaques in transduced arteries and
that LOXIN was able to abrogate plaque induction.
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